Tenaya Therapeutics, Inc. (TNYA): R&D Expense
$68.61M
Year ended 2025-12-31
$61.61M
Trailing 12 months to 2026-06-30
-10.1%
3-year compound annual growth
+17.1%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $68.61M | -20.9% | 2026-03-11, From 2025-01-01 |
| 2024-12-31 | $86.74M | -11.5% | 2026-03-11, From 2024-01-01 |
| 2023-12-31 | $98.04M | +3.7% | 2025-03-10, From 2023-01-01 |
| 2022-12-31 | $94.54M | +73.8% | 2024-03-18, From 2022-01-01 |
| 2021-12-31 | $54.39M | +74.9% | 2023-03-08, From 2021-01-01 |
| 2020-12-31 | $31.10M | n/a | 2022-03-23, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Tenaya Therapeutics, Inc. (TNYA) | 2025-12-31 | $68.61M | -20.9% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $113.03M | -44.5% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $33.56M | -34.6% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $28.52M | -11.2% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $54.17M | -9.0% |
| Compugen Ltd (CGEN) | 2025-12-31 | $22.76M | -8.3% |
| Palisade Bio, Inc. (PALI) | 2025-12-31 | $10.19M | +12.5% |
| Artiva Biotherapeutics, Inc. (ARTV) | 2025-12-31 | $69.54M | +38.2% |
| Cabaletta Bio, Inc. (CABA) | 2025-12-31 | $142.67M | +46.8% |
Compare TNYA, INBX, BDTX, IMA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗